YungJin Pharmaceutical company received U.S. FDA acknowledge in the efficacy of COPD treatment on Phase 1 clinical trial
On Feb 21, YungJin Pharmaceutical company announced that they received U.S. FDA acknowledge in the efficacy of COPD (chronic obstructive pulmonary disease) treatment on Phase 1 clinical trial in the global natural drug development project.
YungJin's global natural medicine drug project (YPL-001:...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
